Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Denai R Milton"'
Autor:
Mingxuan Xu, Coya Tapia, Joud Hajjar, Sharjeel Sabir, Rivka Colen, Priyadharsini Nagarajan, Phyu P. Aung, Jing Gong, Jordi Rodon, Siqing Fu, Bettzy Stephen, Sinchita Roy-Chowdhuri, Hung Le, Vincent Yang, Abdulrazzak Zarifa, Mohamed Elsayed Abdelsalam, Anuja Jhingran, Milind Javle, Shubham Pant, Brett Carter, Denai R. Milton, Ryan Sun, Daniel D. Karp, Eugene Jon Koay, Yali Yang, Ignacio I. Wistuba, Patrick Hwu, Funda Meric-Bernstam, Aung Naing
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 45-52 (2021)
Introduction: For maximum utility of molecular characterization by next-generation sequencing (NGS) and better understanding of tumor microenvironment with immune correlates analysis, biopsy specimens must yield adequate tumor tissue, and sequential
Externí odkaz:
https://doaj.org/article/92b80aa5eeec4ee281f88d023127d548
Autor:
Rebecca Jeun, Priyanka C Iyer, Conor Best, Victor Lavis, Jeena M Varghese, Sireesha Yedururi, Veronica Brady, Isabella C Glitza Oliva, Ramona Dadu, Denai R Milton, Kristy Brock, Sonali Thosani
Publikováno v:
Immunotherapy. 15:417-428
Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients.
Supplementary Methods, Figure Legends, Table Legends from Dual Roles of RNF2 in Melanoma Progression
Autor:
Lynda Chin, Jason Ernst, Alexander J. Lazar, Suhendan Ekmekcioglu, James W. Horner, Timothy P. Heffernan, Denai R. Milton, Michelle C. Barton, Elizabeth A. Grimm, Dong Yang, Amiksha Shah, Jacob B. Axelrad, Maura Williams, Neha S. Samant, Sneha Sharma, Emily Z. Keung, Chang-Jiun Wu, Petko Fiziev, Lawrence N. Kwong, Kadir C. Akdemir, Kunal Rai
This file contains supplementary methods, supplementary figure legends, supplementary table legends and supplementary references.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7095d0bbb71a789f1d7eb2dcfbc2adc3
https://doi.org/10.1158/2159-8290.22530408.v1
https://doi.org/10.1158/2159-8290.22530408.v1
Autor:
Lynda Chin, Jason Ernst, Alexander J. Lazar, Suhendan Ekmekcioglu, James W. Horner, Timothy P. Heffernan, Denai R. Milton, Michelle C. Barton, Elizabeth A. Grimm, Dong Yang, Amiksha Shah, Jacob B. Axelrad, Maura Williams, Neha S. Samant, Sneha Sharma, Emily Z. Keung, Chang-Jiun Wu, Petko Fiziev, Lawrence N. Kwong, Kadir C. Akdemir, Kunal Rai
Supplementary Figure 1. Western blots. Supplementary Figure 2. Graphs showing tumor volume from mice following intradermal injection of (A) HMEL-BRAF^V600E cells, (B) WM115 cells, (C) 1205 Lu cells, and (D) pMEL-NRAS^G12D overexpressing GFP, RNF2 wil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a15e831788ff1e3285cfe08fa304cd37
https://doi.org/10.1158/2159-8290.22530411.v1
https://doi.org/10.1158/2159-8290.22530411.v1
Autor:
Lynda Chin, Jason Ernst, Alexander J. Lazar, Suhendan Ekmekcioglu, James W. Horner, Timothy P. Heffernan, Denai R. Milton, Michelle C. Barton, Elizabeth A. Grimm, Dong Yang, Amiksha Shah, Jacob B. Axelrad, Maura Williams, Neha S. Samant, Sneha Sharma, Emily Z. Keung, Chang-Jiun Wu, Petko Fiziev, Lawrence N. Kwong, Kadir C. Akdemir, Kunal Rai
Description of states in 45-state chromatin state model.This table describes the biological annotation of each chromatin state in 50-state chromatin model from HMEL-BRAFV600E cells from ChromHMM program.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6811ad484f0cf089b3c3445a0c0077fb
https://doi.org/10.1158/2159-8290.22530399.v1
https://doi.org/10.1158/2159-8290.22530399.v1
Autor:
Lynda Chin, Jason Ernst, Alexander J. Lazar, Suhendan Ekmekcioglu, James W. Horner, Timothy P. Heffernan, Denai R. Milton, Michelle C. Barton, Elizabeth A. Grimm, Dong Yang, Amiksha Shah, Jacob B. Axelrad, Maura Williams, Neha S. Samant, Sneha Sharma, Emily Z. Keung, Chang-Jiun Wu, Petko Fiziev, Lawrence N. Kwong, Kadir C. Akdemir, Kunal Rai
Binding sites for RNF2 in HMEL-RNF2WT cells. This file contains list of all chromosomal locations that show enrichment by MACS for RNF2 binding by V5 ChIP-Seq in HMEL-RNF2 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57ee7481b13a89a8e719bb40e892c9e4
https://doi.org/10.1158/2159-8290.22530405.v1
https://doi.org/10.1158/2159-8290.22530405.v1
Autor:
Oren Pasvolsky, Denai R Milton, Adeel Masood, Sophiya S. Sami, Mark R. Tanner, Qaiser Bashir, Samer A. Srour, Neeraj Y. Saini, Jeremy L Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Publikováno v:
Transplantation and Cellular Therapy. 29:S398-S399
Autor:
Oren Pasvolsky, Denai R. Milton, Mikael Rauf, Mark R. Tanner, Qaiser Bashir, Samer Ali Srour, Neeraj Saini, Jeremy L Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Publikováno v:
Journal of Clinical Oncology. 40:e20024-e20024
e20024 Background: Maintenance therapy with single-agent lenalidomide (Len) after autologous hematopoietic stem cell transplantation (autoHCT) for multiple myeloma (MM) is associated with improved progression-free survival (PFS). However, patients wi
Autor:
Ecaterina Elena Dumbrava, Elizabeth M. Burton, Sumit Kumar Subudhi, Denai R. Milton, Ana Aparicio, Timothy A. Yap, Aung Naing, Paul Gettys Corn, Patrick Glen Pilié, Amado J. Zurita, Jennifer Wang, Rodabe Navroze Amaria, Jennifer Leigh McQuade, Isabella Claudia Glitza, Alexander J. Lazar, Funda Meric-Bernstam, Christopher Logothetis, Michael A. Davies, Patrick Hwu, Hussein A. Tawbi
Publikováno v:
Journal of Clinical Oncology. 40:5052-5052
5052 Background: PTEN loss activates the PI3K/AKT signaling pathway, contributes to an immunosuppressive tumor microenvironment, resistance to androgen deprivation therapy and poor clinical outcome in pts with mCRPC. Treatment with anti-PD1 antibodie